Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.

Abstract: Novel diagnostic assay based on the detection of Ki-67 expression to anticipate the response to anti-HIV therapy

Abstract: A family of pyrazolo[3,4-d]pyrimidine derivatives (SPPs) with different substituents on the pyrimidine and pyrazolo rings have been characterized with a panel of tests demonstrating their effects in cell proliferation, toxicity, apoptosis and inhibition of virus replication. We have identified compounds and molecular structures suitable for the treatment of viral infection because they have antiviral activity, anti-proliferative activity or, preferably, both so that, as a single molecule, they both limit T cell hyperactivation and inhibit virus replication. These compounds are not toxic at effective concentrations and are poorly apoptotic. Other nontoxic compounds within this family with excellent anti-proliferative and apoptotic features are potentially effective as anti-cancer drugs.

Abstract: A molecular delivery complex specific to antigen-presenting cells is formed from a non-viral gene delivery system complexed with foreign genetic material. The complex then enters the targeted cells through a specific receptor and overcomes the degradation mechanism, so that functional uptake of the foreign genetic material, or transduction, of the cell, results in gene expression. The invention also includes a method for genetic immunization without a needle.

Abstract: Pharmaceutical composition, containing fixed doses of hydroxyurea and didanosine, a method of manufacturing such composition, and to the use of the composition for the treatment of retroviral infections.

Abstract: Diagnostic assay of antigen-specific T-cell precursors to determine the immunological status of patients suffering in chronic infectious diseases and to anticipate the disease progression and the response to therapy

Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3? LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3? LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse- transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3′ LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

Abstract: Structured Treatment Interruptions of drug therapy for Human Immunodeficiency Virus infection can be used to enhance HIV-specific immune responses, thereby allowing the individual to control viral replication after interrupting the drug treatment. Immunoregulatory adjuvants can further increase these immune responses. A diagnostic method for the immune status of the patient that controls HIV includes measurements of viral load and production of both IFN-gamma and IL-10.

Abstract: A molecular delivery complex specific to antigen-presenting cells is formed from a non-viral gene delivery system complexed with foreign genetic material. The complex then enters the targeted cells through a specific receptor and overcomes the degradation mechanism, so that functional uptake of the foreign genetic material, or transduction, of the cell, results in gene expression. The invention also includes a method for genetic immunization without a needle.

Abstract: A molecular delivery complex specific to antigen-presenting cells is formed from a a non-viral gene delivery system complexed with foreign genetic material. The complex then enters the targeted cells through a specific receptor and overcomes the degradation mechanism, so that functional uptake of the foreign genetic material, or transduction, of the cell, results in gene expression. The invention also includes a method for genetic immunization without a needle.

Abstract: A method for genetic immunization comprises administering a highly active antiretroviral therapy to control viral replication, and then administering a transcutaneous DNA vaccine.

Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse- transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

Abstract: A method for treating HIV infection in human beings comprising the step of measuring viremia, and if viremia is less than 50,000-100,00 copies per milliliter, administering a combination of compounds selected from the group consisting of hydroxyurea, and one or more reverse transcriptase inhibitors.